THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME

WIPO Patent Application WO/2006/115135

A1

It is intended to provide a therapeutic agent for irritable bowel syndrome (IBS) excellent in efficacy and safety. A bombesin 2 (BB2) receptor antagonist, as represented by RC-3095, was shown to be a therapeutic agent for irritable bowel syndrome (IBS) exerting an excellent efficacy in both an abdominal symptom and bowel movement disorder. Therefore, according to the invention, it became possible to provide a therapeutic agent for irritable bowel syndrome (IBS) containing as an active ingredient, a bombesin 2 (BB2) receptor antagonist exerting an excellent efficacy in both an abdominal symptom and bowel movement disorder.

YAMANO MAYUMI (JP)

PCT/JP2006/308173

November 02, 2006

April 19, 2006

Click for automatic bibliography generation  

ASTELLAS PHARMA INC (JP)
YAMANO MAYUMI (JP)

A61K45/00; A61K31/167; A61K31/341; A61K31/404; A61K31/4365; A61K31/438; A61K31/4439; A61K31/4545; A61K38/00; A61K38/08; A61P1/00; A61P1/10; A61P1/12

WO2002049644A1	2002-06-27
WO1998007718A1	1998-02-26

PINSKI J. ET AL.: "High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of defferent routes of administration", REGULATORY PEPTIDES, vol. 41, no. 3, 1992, pages 185 - 193, XP000609050
ISHIKAWA M. ET AL.: "A Clinical Study on Regulation of Motility of Digestive Tract by Gastrointestinal Hormones", JAPANSE JOURNAL OF MEDICINE, vol. 14, no. 1, 1975, pages 21 - 25, XP003006892
See also references of EP 1872795A4

Morita, Hiroshi c/o Astellas Pharma Inc. (Intellectual Property 3-11, Nihonbashi-Honcho 2-chom, Chuo-ku Tokyo 11, JP)

View/Download PDF      PDF Help

Previous Patent: NOVEL BENZOFURAN DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE DERIVATI...

Next Patent: ALLERGY-SUPPRESSIVE COMPOSITION, ALLERGY-SUPPRESSIVE FOOD AND ALLERGY-SUPPRESSIVE AGENT